ABVC Biopharma Key Fundamental Indicators
| ABVC Stock | USD 1.67 0.06 3.47% |
As of the 15th of February 2026, ABVC Biopharma shows the Mean Deviation of 3.23, market risk adjusted performance of (0.44), and Variance of 19.0. ABVC Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.
ABVC Biopharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 52.2823 | Revenue | Earnings Share (0.28) |
ABVC | Select Account or Indicator | Build AI portfolio with ABVC Stock |
ABVC Biopharma Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Biopharma Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Biopharma Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Biopharma Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Fundamental Market Drivers
ABVC Upcoming Events
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
ABVC Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for ABVC Biopharma is extremely important. It helps to project a fair market value of ABVC Stock properly, considering its historical fundamentals such as Shares Outstanding. Since ABVC Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ABVC Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ABVC Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 1.045 | Return On Assets | Return On Equity |
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
ABVC Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ABVC Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ABVC Biopharma.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in ABVC Biopharma on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding ABVC Biopharma or generate 0.0% return on investment in ABVC Biopharma over 90 days. ABVC Biopharma is related to or competes with Reviva Pharmaceuticals, Grace Therapeutics, PDS Biotechnology, Actinium Pharmaceuticals, Jupiter Neurosciences, Tvardi Therapeutics, and Lantern Pharma. ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet me... More
ABVC Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ABVC Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ABVC Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 23.14 | |||
| Value At Risk | (6.85) | |||
| Potential Upside | 7.31 |
ABVC Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ABVC Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ABVC Biopharma's standard deviation. In reality, there are many statistical measures that can use ABVC Biopharma historical prices to predict the future ABVC Biopharma's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.45) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ABVC Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ABVC Biopharma February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 3.23 | |||
| Coefficient Of Variation | (613.57) | |||
| Standard Deviation | 4.36 | |||
| Variance | 19.0 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 23.14 | |||
| Value At Risk | (6.85) | |||
| Potential Upside | 7.31 | |||
| Skewness | (0.54) | |||
| Kurtosis | 1.68 |
ABVC Biopharma Backtested Returns
ABVC Biopharma secures Sharpe Ratio (or Efficiency) of -0.18, which signifies that the company had a -0.18 % return per unit of volatility over the last 3 months. ABVC Biopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm ABVC Biopharma's Mean Deviation of 3.23, variance of 19.0, and Market Risk Adjusted Performance of (0.44) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.59, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ABVC Biopharma will likely underperform. At this point, ABVC Biopharma has a negative expected return of -0.79%. Please make sure to confirm ABVC Biopharma's accumulation distribution, and the relationship between the potential upside and day median price , to decide if ABVC Biopharma performance from the past will be repeated in the future.
Auto-correlation | 0.63 |
Good predictability
ABVC Biopharma has good predictability. Overlapping area represents the amount of predictability between ABVC Biopharma time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ABVC Biopharma price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current ABVC Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.67 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
ABVC Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, ABVC Biopharma has 24.3 M of shares currently outstending. This is 86.54% lower than that of the Biotechnology sector and 77.26% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 95.75% higher than that of the company.
ABVC Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ABVC Biopharma's current stock value. Our valuation model uses many indicators to compare ABVC Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ABVC Biopharma competition to find correlations between indicators driving ABVC Biopharma's intrinsic value. More Info.ABVC Biopharma is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . At present, ABVC Biopharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ABVC Biopharma's earnings, one of the primary drivers of an investment's value.ABVC Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ABVC Biopharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ABVC Biopharma could also be used in its relative valuation, which is a method of valuing ABVC Biopharma by comparing valuation metrics of similar companies.ABVC Biopharma is currently under evaluation in shares outstanding category among its peers.
ABVC Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (1.47) % | ||||
| Current Valuation | 41.72 M | ||||
| Shares Outstanding | 24.3 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 3.27 % | ||||
| Number Of Shares Shorted | 250.99 K | ||||
| Price To Book | 3.37 X | ||||
| Price To Sales | 50.86 X | ||||
| Revenue | 509.59 K | ||||
| Gross Profit | 797.92 K | ||||
| EBITDA | (4.34 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 2.99 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 3.2 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (1.81 M) | ||||
| Short Ratio | 4.61 X | ||||
| Earnings Per Share | (0.28) X | ||||
| Target Price | 2.02 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 40.58 M | ||||
| Total Asset | 7.54 M | ||||
| Retained Earnings | (68.95 M) | ||||
| Working Capital | (4.38 M) | ||||
| Net Asset | 7.54 M |
About ABVC Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABVC Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABVC Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABVC Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 93.3 K | 97.9 K | |
| Total Revenue | 586 K | 615.3 K | |
| Cost Of Revenue | 686.70 | 652.37 | |
| Stock Based Compensation To Revenue | 6.26 | 5.95 | |
| Sales General And Administrative To Revenue | 8.89 | 15.03 | |
| Research And Ddevelopement To Revenue | 0.40 | 0.38 | |
| Capex To Revenue | 0.16 | 0.15 | |
| Revenue Per Share | 0.05 | 0.05 | |
| Ebit Per Revenue | (8.31) | (8.73) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 1.045 | Return On Assets | Return On Equity |
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.